Sight Sciences announces 1,000th TearCare customer installation

Sight Sciences announced the 1,000th installation of its TearCare System. The TearCare System is FDA cleared and indicated for the application of localized heat therapy in adult patients with evaporative dry eye disease due to meibomian gland dysfunction, when used in conjunction with manual expression of the meibomian glands. "We are thrilled that over 1,000 eye care practices have chosen the TearCare(R) System to treat dry eye caused by MGD," said Paul Badawi, co-founder, and Chief Executive Officer of Sight Sciences. "We designed TearCare(R) to treat the underlying cause of MGD and restore production of healthy tears. The over 1,000 votes of confidence that we have received from eye doctors across the United States along with our outstanding clinical and real-world outcomes, demonstrate the increasing importance and acceptance of effective interventional dry eye treatment. We are particularly proud to have an ophthalmologist of Dr. Becker’s clinical reputation and expertise represent this milestone occasion."